

Ventricular Septal Defect

What the Nurse Caring for a Patient with CHD Needs to Know

Courtney Petro, BSN, RN, CCRN

Registered Nurse, Cardiovascular ICU,
Lucile Packard Children's Hospital at Stanford

Melanie Sojka, MSN, RN, CPNP-AC/PC

Pediatric Nurse Practitioner, Cardiac & Thoracic Surgery,
University of Chicago Medicine, Comer Children's Hospital

Grace Macek, MSN, RN, PNP-BC

Pediatric Nurse Practitioner, Cardiac & Thoracic Surgery,
University of Chicago Medicine, Comer Children's Hospital

Jennifer Newcombe, MSN, CNS, CPNP-AC/PC

Nurse Practitioner, Pediatric Cardiothoracic Surgery,
Loma Linda University Children's Hospital

Dorothy M Beke, RN, MS, CPNP-PC/AC

CICU Clinical Nurse Specialist and Cardiology Clinic NP,
Boston Children's Hospital


Embryology

- One of most common congenital heart defects (CHD)
- Intraventricular septum divides right (RV) & left (LV) ventricles
 - Consists of 3 separate septa
 - Beginning in 5th week embryonic development
 - Completely formed and closed by 7th-8th week embryonic development
- Septum results from:
 - Growth of muscular portion upward from ventricular floor towards endocardial cushions
 - Growth of subendocardial tissue from right side of endocardial cushion
 - Fuses with aorticopulmonary septum
 - Fuses with muscular portion
- Causes of ventricular septal defect (VSD)
 - Unclear
 - Multifactorial
 - Genetic/chromosomal syndromes (trisomy 13, 18, 21/ Holt-Orem, Cornelia de Lang)
 - Majority not associated with other defects or syndromes
 - More common in premature or low-birthweight infants

Anatomy

- Results when interventricular septum fails to close (See illustration below for locations and types of VSDs)

- May occur in any part of the septum
- May occur in more than one location



Illustrations reprinted from PedHeart Resource. www.HeartPassport.com.
 © Scientific Software Solutions, 2016. All rights reserved

- Abnormal communication along septum between right & left ventricles
 - Disruption in fusion of 3 separate septa
 - Size and anatomical location
 - May be single or multiple defects
 - Varies with 4 major locations
 - Perimembranous (Membranous, infracristal, conoventricular malalignment including tetralogy of Fallot and double outlet defects) (Number 2 in above illustration)
 - Located in upper portion of septum
 - Most common - 70-80%
 - Frequently close in first year of life – 30-50%
 - Conoventricular defects do not spontaneously close
 - Outlet (Supracristal, conal, subpulmonary, subarterial) (Number 1 in above illustration)
 - Incomplete fusion along aortopulmonary septum with endocardial cushions & muscular portion
 - Located just beneath pulmonary valve

- May involve prolapse of aortic valve leaflet
 - Results to damage in aortic valve
 - May result in aortic valve insufficiency
 - Spontaneous closure uncommon
- Inlet or Canal VSDs (Number 6 in above illustration) (Number 6 in above illustration)
 - Lie beneath septal leaflet of TV
 - May be referred to as an atrioventricular septal defect, but does not involve either atrioventricular valve
 - Will not spontaneously close
- Muscular or trabecular VSDs (Numbers 3,4, & 5 in above illustration)
 - Less common – 5-20%
 - Completely surrounded by muscular tissue
 - May appear as single defect on LV side and multiple defects on RV side due to trabeculations (criss-crossing fibrous and muscular tissue strands)
 - May close spontaneously
 - “Swiss cheese” septum
 - Multiple defects
 - Involve all septal regions
- Associated with other cardiac defects: Atrial Septal Defect (ASD), Patent Ductus Arteriosus (PDA), Coarctation of the Aorta (CoAo), subvalvar Aortic Stenosis (AS), or subpulmonic stenosis (PS)
- Multiple VSDs often present with: Tetralogy of Fallot (TOF), Double-Outlet Right Ventricle (DORV)
- May be acquired in older patients from post-surgical leak, trauma, or myocardial infarction

Physiology

- Abnormal blood flow across defect in ventricular septum
- Affected by:
 - Size of defect
 - Primary variable
 - Impacts shunt and need for repair
 - VSDs <25% of the aortic annulus diameter
 - Small
 - Minimal, if any, left-to-right shunting
 - Potential for spontaneous closure based upon location
 - VSDs 25%-75% of the aortic annulus diameter
 - Little to moderate left to right shunting
 - No pulmonary artery hypertension
 - May be mild to moderate pulmonary overcirculation
 - May have symptoms of congestive heart failure (CHF)
 - Can be managed with medications

- May improve as the patient grows and the defect starts to close
 - VSDs >75% of the aortic annulus diameter
 - No restriction to flow
 - Moderate to large volume shunt
 - Pulmonary overcirculation with CHF symptoms
 - Increased pulmonary venous return
 - LA and LV dilation
 - LV hypertrophy
 - Increased RV volume
 - Increased pulmonary blood flow
 - Increased pulmonary pressures
 - May result in pulmonary artery hypertension (PAH)(See Peds/Neo Problem Guideline on Pulmonary Hypertension)
 - Long standing PAH may result in Eisenmenger’s Syndrome (See Adult Problem Guideline on Eisenmenger’s Syndrome)
 - Most likely requires closure
- Resistance to flow
 - Pulmonary vascular resistance (PVR)
 - Newborn
 - Pulmonary pressure \geq systemic pressures
 - Rapidly fall with first few breaths after birth
 - Reaches normal adult pressures within first 2 months of age (Normal mean pressures \leq 25 mmHg after first few weeks of life)
 - Decrease accelerated by:
 - Supplemental oxygen
 - Pulmonary vasoactive medications (iNO, sildenafil)
 - Decreased resistance increases flow across defect (left-to-right shunt)
 - Normal maturation of pulmonary vascular bed
 - Usually occurs by 2 months of age
 - RV pressure usually drops to $\sim 1/3^{\text{rd}}$ to $1/2$ of LV pressure by ~ 2 weeks; however in the presence of a VSD, RV pressure may take longer to decrease.
 - Allows for development of pulmonary overcirculation
 - Systemic vascular resistance (SVR)
 - Newborn
 - Systemic pressures = pulmonary pressures
 - Left sided lesions increase systemic resistance
 - Coarctation of the aorta (CoA), aortic valve (AV) stenosis
 - Vasoconstriction

- Increased left-sided systolic pressure increases flow to RV (left-to-right shunt)

Procedures/Interventions

- Indications for Intervention:
 - Infants with greater than 2:1 shunt
 - Large sized VSDs and significant CHF
 - Medical treatment of CHF
 - Diuretic therapy
 - Digoxin/ angiotensin converting enzyme (ACE) inhibitors
 - Increase caloric intake
 - Goals: control symptoms and allow infant to grow
 - Surgical closure
 - Early closure (~ less than 3 months of age)
 - Unable to manage CHF and provide for somatic growth
 - Infants with shunts 1.5:1
 - Moderate sized VSD
 - May usually be followed for up to 5 years of age to maximize chance of spontaneous closure
 - Shunts less than 1.5:1
 - Small VSD
 - Require close follow-up
 - Outlet VSDs
 - May see prolapse of leaflet of AV and develop progressive aortic regurgitation (AR)
 - Repair before significant aortic regurgitation (AR) develops
- Surgical intervention - complete repair via open heart surgery (OHS)
 - Patch closure
 - Requires cardiopulmonary bypass & sternotomy
 - Majority of membranous & inlet VSDs closed through the transatrial approach
 - Repair thru tricuspid valve (TV)
 - May have obstructed visualization from valve leaflet
 - Requires retraction and sometimes detachment of valve leaflet and subsequent repair of TV
 - Some defects require a right ventriculotomy or pulmonary artery approach
 - Closed with patch material (Dacron or Polytetrafluoroethylene [PTFE])
 - Direct suture closure for very small defects
 - Risks
 - Injury to AV or conduction system
 - Residual VSD
 - Diminished RV function with ventriculotomy
 - Intraoperative transesophageal echocardiography (TEE)
 - Assess repair
 - Rule out residual VSD

- Assess competence of TV and AV
 - Assess ventricular function
- Surgical intervention – palliative
 - Pulmonary Artery Band (PAB)
 - Requires sternotomy; cardiopulmonary bypass not required
 - Controls symptoms related to CHF
 - Allows infants to grow and reach appropriate size for surgical repair
 - Rarely indicated
 - Exceptions: infants < 2.5 kg with multiple/complex defects and/or intractable CHF
- Combined Surgical/ cardiac catheterization intervention (Hybrid intervention)
 - Indications
 - Patients too small for percutaneous catheter system
 - Part of repair of complex lesion
 - Visualization of VSD difficult
 - Periventricular closure
 - Requires sternotomy but avoids cardiopulmonary bypass
 - Placement of percutaneous device directly through the right ventricular (RV) free wall
- Cardiac catheterization intervention
 - Percutaneous closure
 - Avoids sternotomy & cardiopulmonary bypass
 - Device is placed during cardiac catheterization
 - Muscular VSDs may be amenable to device closure

Specific considerations

- Pre-operative considerations
 - Age
 - Consider size and location of defect
 - Premature neonates
 - Consider size of defect relative to body size to determine timing of surgical correction
 - Neonates
 - Due to elevated PVR development of CHF rare in the first few weeks of life (See resistance to flow section)
 - Do not administer supplemental oxygen unless oxygen saturations persistently < 75%
 - Infants and children
 - May be managed medically
 - Require surgical correction
 - CHF unresponsive to medical management,
 - Growth failure
 - Outlet and inlet defects
 - Health status
 - Recent/frequent viral respiratory infections
 - Supportive management until cultures negative

- Surgery delayed until patients are symptom free to minimize post-bypass pulmonary complications
 - Failure to thrive
 - Consider nasogastric, high caloric feeding
 - Attempt to achieve positive caloric balance
- Postoperative (See Peds/Neo Problem Guidelines for Postoperative Management)
 - Most common open heart surgery for CHD
 - Ventilation
 - Patients beyond infancy may be extubated in OR
 - Neonates and infants may require ventilator support and aggressive diuresis before extubation
 - Patients with respiratory viral infections preoperatively may require extended intubation
 - Patients with pre-operative respiratory syncytial virus (RSV) should have negative cultures and be asymptomatic prior to surgery to minimize post-operative complications
 - Patients with pre-operative PAH will require pulmonary vasodilators (iNO, IV pulmonary vasodilators) (See Peds/Neo Problem Guidelines for Pulmonary Hypertension)
 - Inotropic support
 - Majority with minimal inotropic support
 - Repair of VSD with complex lesions or PAH
 - May also consider pulmonary vasodilators
 - Monitor for the following complications:
 - Arrhythmias (See Peds/Neo Problem Guidelines for Arrhythmia Management)
 - Most patients who have cardiopulmonary bypass surgery have temporary epicardial wires placed in OR
 - Complete Heart Block
 - Typically transient 24-48 hours
 - May be permanent and require placement of a permanent pacemaker, usually after 7-10 days
 - Supraventricular Tachycardia (SVT) or Junctional Ectopic Tachycardia (JET)
 - Residual VSD
 - Common to have some residual leaks around patch which often eventually close with endothelialization
 - Assessment
 - Operating room
 - Analysis of RA and PA saturations
 - Echocardiography [Transesophageal (TEE) or Transthoracic (TTE)]
 - Intensive care unit
 - Desaturation
 - Increased pulmonary pressures
 - Decreased systemic pressures

- VSD patch dehiscence with low cardiac output
- Pulmonary hypertensive crisis
 - Patients with elevated PVR preoperatively or long-standing pulmonary over-circulation (See Ped/Neo Problem Guidelines for Pulmonary Hypertension)
 - Monitor PA pressures if PA line available
 - Follow pulmonary hypertension precautions
 - Avoid noxious stimulation
 - Fastidious pulmonary toilet (pre-medicate prior to suctioning)
 - Hyperventilation
 - Oxygenation
 - Strict acid / base control
 - Inhaled nitric oxide - potent pulmonary vasodilator
 - Sedation/paralysis
- Post-catheter device monitoring:
 - Bleeding at puncture site
 - Arrhythmias (Complete Heart Block)
 - Device may put pressure on the septum close to the left and right bundle branches
 - Valvar regurgitation
 - Risk of “trapping” the aortic, tricuspid, or mitral valve leaflets in the device
 - Device embolization

Long-Term Problems/Complications

- Structural Complications
 - Residual VSD
 - AI secondary to aortic cusp prolapse
 - Supralvalvar pulmonic stenosis after prior placement of PAB
 - Subaortic membrane (rare)
 - Right ventricle muscle bundle hypertrophy (rare)
- Arrhythmias (See Peds/Neo Problem Guidelines for Arrhythmia Management)
 - Transient post-operative heart block
 - At risk of developing complete heart block
 - May require pacemaker placement
 - Ventricular arrhythmias
 - Monitor with periodic electrocardiograms (ECG), Holter monitor
 - Increased with ventriculotomy
- Heart Block requiring pacemaker placement (see Peds/Neo Problems Guidelines for Pacemakers)
 - Pacemaker interrogation every 3-6 months
 - Generator changes ~ every 6-10 years
 - Lead malfunction or fracture
 - Cardiovascular implantable electronic device (CIED) infection

Routine Cardiology Care for Surgical and Catheter Intervention

- Routine follow-up interval
 - Every 1-2 years by a cardiologist trained in Congenital Heart Disease (CHD) until 18 years of age
 - Adults
 - No residual VSD, no associated lesions and normal pulmonary pressure
 - Does not require continued follow-up at a regional ACHD center
 - Small residual VSD
 - Follow up visit every 3 to 5 years at an Adult CHD (ACHD) regional center
 - Device closure of a VSD
 - Follow up visit every 1 to 2 years at an ACHD center
 - Depends on the location of the VSD
- Cardiac studies as indicated by assessment/symptoms
 - Transient post-operative heart block, at least a yearly ECG
 - Echocardiogram
- Endocarditis prophylaxis recommendations (AHA, 2015)
 - Six months post-surgical repair/device placement
 - Longer if a residual defect is present

References:

Allen. H., Driscoll, D., Shaddy, R. & Feltes, T. (2013). Moss and Adams' heart disease in infants, children, and adolescents (8th ed.). Philadelphia: Lippincott Williams & Wilkins.

American Heart Association. (2015). Retrieved from www.heart.org

Bhatt et al. (2015). Congenital heart disease in the older adult. A scientific statement from American Heart Association. *Circulation*, 131, 1884-1931.

Cook, RN, MS, PNP-BC, L. (2013). CVICU Bedside Cardiac Defect Reference Book (p. 7). Palo Alto, California: Lucile Packard Children's Hospital.

Everett, A. D., & Lim, D. S. (2010). *Illustrated Field Guide to Congenital Heart Disease and Repair*. (3rd ed.) Charlottesville, VA: Scientific Software Solutions, Inc.

Ferri, M.D., F.A.C.P., F. (2016). Ventricular Septal Defect. In Ferri's Clinical Advisor 2016 (1st ed., pp. 1295-1297). Philadelphia, Pennsylvania: Elsevier.

McRae, ME. (2015). Long-term Outcomes After Repair of Congenital Heart Defects: Part 1. *The American Journal of Nursing*, 115 (1), 24-35.

Moore, K.L. & Persaud, T.V.N. (2008). The cardiovascular system: in *The Developing Human. Clinically Oriented Embryology* (8th ed). Philadelphia, PA: Saunders, an imprint of Elsevier Inc.

Nichols, DG, Ungerleider, RM, Spevak, PJ, Greeley, WJ, Cameron, DE, Lappe, DG, & Wetzel, RC. (2006). *Critical Heart Disease in Infants and Children* (2nd ed.). Philadelphia, PA: Mosby Elsevier.

Park, M. (2016). *The pediatric cardiology handbook* (5th ed.). Philadelphia: Mosby.

Rojas, C., Jaimes, C., & Abbara, S. (2013). Ventricular Septal Defects: Embryology and Imaging Findings. *Journal of Thoracic Imaging*, 28(2), W28-W34.

Rummell, M. (2013) Ventricular Septal Defect (VSD): Acyanotic Defects: Left-to-right Shunts. Chapter 8 Cardiovascular Disorders. In M. F. Hazinski (Ed.). *Nursing Care of the Critically Ill Child* (3rd ed.). Philadelphia, PA: Elsevier.

Warnes et al. (2015). ACC/AHA guidelines for management of adults with congenital heart disease: Executive Statement. *Circulation*, 118, 2395-2451.

Wilkoff et al. (2008). HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations. *Heart Rhythm*, 5, 907-925.

Illustrations reprinted from PedHeart Resource. www.HeartPassport.com. © Scientific Software Solutions, 2016. All rights reserved.

2/2016